Evidence map›Paper›PMID 41803109›Full record

ArticleSignal transduction and targeted therapy2026

Nature-inspired confined cascade enzyme nanoreactors for targeted atherosclerosis therapy.

Yuehuang Wu, Hongping Xia, He Ding, Mengmeng Long, Sen Yan, Miao Zhang, Jingyi Sheng, Ning Gu

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuehuang Wu *School of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu, China.
Hongping Xia *Zhongda Hospital, School of Medicine & Cancer Institute of Xuzhou Central Hospital & Jiangsu Provincial Key Laboratory of Critical Care Medicine & Institute for Advanced Study of Life and Health, Southeast University, Nanjing, China.ORCID http://orcid.org/0000-0001-6454-2333
He DingJiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Mengmeng LongJiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Sen YanJiangsu Key Laboratory for Cardiovascular Information and Health Engineering Medicine, Institute of Clinical Medicine, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing, China.
Miao ZhangJiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Jingyi ShengSchool of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu, China. shengjingyi@seu.edu.cn.
Ning GuJiangsu Key Laboratory for Cardiovascular Information and Health Engineering Medicine, Institute of Clinical Medicine, Nanjing Drum Tower Hospital, Medical School, Nanjing University, Nanjing, China. guning@nju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative stress and excessive inflammatory responses are major drivers of atherosclerosis (AS) formation and progression. In this study, we report a nature-inspired nanoreactor (named USPB@SeDMSN@NM) with superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) multienzymatic activities for targeted atherosclerosis therapy. The confined cascade nanocatalyst (USPB@SeDMSN) is designed by assembling ultrasmall Prussian blue nanoparticles (USPB NPs, SOD and CAT mimics) into the large pores of selenium (Se)-doped dendritic mesoporous silica nanoparticles (SeDMSNs, GPx mimics). The DMSN provides abundant immobilization sites for USPB NPs and Se to sequentially scavenge reactive oxygen species (ROS) in a cascade manner and forms confined reaction environments to significantly increase the local concentration of substrates and overall catalysis efficiency, which is inspired by multienzyme complexes (MECs) in nature. The neutrophil membrane was coated onto USPB@SeDMSN to endow the nanoplatforms with the ability to target atherosclerotic plaques. In vitro and in vivo results demonstrated that this nature-inspired enzyme cascade nanoreactor efficiently mitigated inflammation in macrophages and endothelial cells by scavenging various radicals and inhibited foam cell formation by reducing lipid accumulation in macrophages. Moreover, it has significant antiaging effects, protecting DNA from oxidative damage and slowing the onset of cell senescence. By conducting confined SOD-CAT/GPx cascade reactions for high-efficiency plaque microenvironment modulation, the USPB@SeDMSN@NM nanoreactor offers a powerful modality for targeted atherosclerosis therapy. This work highlights the potential of this biomimetic confined nanoreactor with cascaded multienzyme-like activities as an antioxidant and antisenescence agent for atherosclerosis treatment.

Indexed as

AtherosclerosisNanoparticlesAnimalsCatalaseGlutathione PeroxidaseHumansMacrophagesMiceOxidative StressReactive Oxygen SpeciesSeleniumSilicon DioxideSuperoxide DismutaseCatalaseGlutathione PeroxidaseReactive Oxygen SpeciesSeleniumSilicon DioxideSuperoxide Dismutase

Identifiers

PMID41803109
PMCPMC12972303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.